Direct reporting network in December 29th (economic information network) in December 28th, the United States and the United States in 2015 second provisional shareholders' meeting held in Puning, the General Assembly adopted the non-public offering of the company's non-public offering plan, the company's 2015 annual employee stock ownership plan (Draft) (non-public offering subscription), and other motion. Kang Mei pharmaceutical chairman, general manager Ma Xingtian attended and presided over the meeting, vice chairman, deputy general manager Xu Dongjin, director, secretaries, deputy general manager Qiu Xiwei and shareholders, shareholders representing a total of 51 people attended the meeting.

By the combination of on-site and online voting Conference unanimously adopted Kangmei pharmaceutical non public offering of stock options motion, "Kangmei Pharmaceutical Co., Ltd. 2015 annual employee stock ownership plan (Draft) (non-public offering subscription), and 14 motion. The number of voting shares held by the shareholders at the meeting is 33.48% of the number of voting shares held by the company, which is in accordance with the provisions of the company law and the articles of association. Guoco lawyers (Guangzhou) firm's attestation of the conference, grandall law firm (Guangzhou) said that the general meeting of shareholders convened and held the procedure, to attend the meeting personnel qualification, voting procedures and the results of the vote are in line with the "company law", "Securities Law", the shareholders' meeting of the relevant provisions of the rules and Kangmei pharmaceutical charter, General Assembly resolution legitimate and effective.

The company said that the steady increase will provide long-term stable financial support for the company to further consolidate the traditional Chinese medicine industry chain business system, improve the company's profitability and market competitiveness, strengthen the integration of traditional Chinese medicine business model and business system, to further increase investment in various business lines, expanding avenue of medicinal herbs planting and management of varieties and regions, to further optimize the Chinese herbal medicine professional market and the virtual market exchange links, further expand the company's market influence, further expand the company's production capacity and market size, further optimize the sales network integration and market Management, to further promote the standardization of Chinese herbal medicine construction, to further expand the company's modern medicine logistics distribution system to cover and improve the efficiency of its operation.

On the other hand, the increase will strengthen the capital strength, accelerate the implementation of the company's Internet + big health strategy. Kang Mei pharmaceutical industry as the current domestic industry in the field of business chain is the most complete, the most abundant health resources, the integration of one of the most powerful leading enterprises, rapid layout and enhance the pharmaceutical electricity suppliers (B2B, B2C), wisdom pharmacy, community health, mobile health services, etc., has been initially completed Internet + big health business system strategy layout. Strong financial backing will Kangmei pharmaceutical leveraging the Internet of implementation enterprises bigger and stronger and the transformation and upgrading, at one stroke to become the leading domestic Internet medical and health industry.

Meeting, a to attend the shareholders said that not long ago, Tu youyou won the Nobel Prize for the eyes of the world have paid attention to the traditional Chinese medicine. Now there is a great concern of the Chinese medicine community event occurs, after a lapse of 32 years, the State Council executive meeting adopted the Chinese medicine law (Draft), and the first submitted to the National People's Congress for 21 days, once the draft legislation passed, will become the first national law on traditional Chinese medicine. Kang Mei pharmaceutical industry as a leading enterprise in the domestic pharmaceutical industry, the concept of the first shares of Chinese medicine, with the country to accelerate the development process of Chinese medicine industry, the company's value and development prospects of Kang beauty pharmaceutical industry is bound to highlight day by day, the future development of a large.

Shareholders stressed that the Huaan information management and other institutions and company executives involved in the subscription, fully reflects the firm value of investment and the company's confidence in the good development of the situation. As General Secretary Xi Jinping said, current TCM revitalization and development ushered in the day, geography, and the opportunity, for the construction of health of China, to achieve a great journey of Chinese dream compose the new chapter, I believe record breaking success of Kangmei pharmaceutical industry will also in this great opportunity spectrum to write a new journey, past Kang beauty of steady development and return let us have enough confidence and optimistic about future of the sig. 3

(original title: Kang Mei pharmaceutical 8 billion 100 million set by the motion to increase the motion Ma Xingtian interim shareholders' meeting

Editor: Xiao Shen

Interpretation of the news hot spots, showing sensitive events, more exclusive analysis, as in the "direct" micro channel, scan two-dimensional code free reading.